Project Grant R44HL174221
Award Date
9/20/24
Completion Date
6/30/25
Dollars Obligated
$301K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Louisville, KY 40206, USA
Similar Awards
This $128,047 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of an innovative urine-based diagnostic test for obstructive sleep apnea (OSA). The grant recipient, PGXL Technologies LLC, is collaborating with the University of Louisville Research Foundation to create a urine collection kit and validate a multiplex immunoassay panel using four protein biomarkers to detect...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $615,621 to Powell Mansfield, Inc. to develop and validate a diagnostic tool for obstructive sleep apnea (OSA) called deep learning-enhanced transmembranous electromyography (DL-TMEMG).
The project aims to establish the feasibility of TMEMG to accurately diagnose OSA patients, optimize the deep learning algorithm, and then demonstrate...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is for the development and use of a novel wearable sensor system called "Sleeptronix" to assess sleep, temperature, and cortisol levels in individuals with obstructive sleep apnea (OSA). The $253,500 award will be used to refine the Sleeptronix system and evaluate its ability to accurately measure clinically-used metrics like...
This $1,420,164 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to simultaneously evaluate changes in cerebral oxygen metabolism and upper airway anatomy in obstructive sleep apnea (OSA) patients. The key objectives are to: 1) optimize a time-resolved MRI protocol and synchronized airway plethysmography to detect metabolic and structural changes during induced apneas; 2)...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $288,043 to Glycodots LLC to develop a novel rapid diagnostic test (EPX-RDT) for detecting eosinophil peroxidase (EPX) in nasal swab samples.
The goal is to create a point-of-care device that can non-invasively diagnose and guide asthma treatment by quantifying EPX levels, which are associated with asthma type and severity. The...
This $1,415,112 Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to evaluate a telehealth-delivered adaptive intervention to promote continuous positive airway pressure (CPAP) therapy adherence and improve health outcomes for adults newly diagnosed with obstructive sleep apnea (OSA). The key objectives are to: 1) compare the effects of motivational enhancement, device support, and standard...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $426,717 to The University of Iowa to develop a novel 3D dynamic MRI (3D-DMRI) scheme to quantify airway collapse in patients with obstructive sleep apnea (OSA). The goal is to create an alternative to the current standard drug-induced sleep endoscopy (DISE) procedure, which has several limitations, in order to better characterize the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $711,226 to the University of California, Los Angeles (UCLA) to investigate the relationship between obstructive sleep apnea (OSA) and brain changes.
The research aims to examine regional brain temperatures, metabolites, and antioxidant levels in OSA patients compared to healthy controls, as well as assess whether continuous...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) totaling $745,121 will support research at the University of Missouri System investigating the relationship between obstructive sleep apnea (OSA) and cardiovascular dysfunction. The research aims to elucidate the physiological and molecular mechanisms by which OSA-induced cellular senescence leads to vascular dysfunction, and to evaluate whether selectively...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $400,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Electronic Biosciences, Inc., a small business biotechnology company. The grant will fund the development of a compact, low-cost analytical device to precisely characterize lipoprotein particles in blood. This advanced technology will provide researchers and clinicians with new capabilities to evaluate cardiovascular disease risk and...